Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
14 juin 2024 03h00 HE
|
Janssen Cilag International NV
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of...
Johnson & Johnson MedTech gathers multi-disciplinary expert group to optimise lung cancer care and dialogue between patients and their healthcare team
30 mai 2024 08h39 HE
|
Johnson & Johnson MedTech
A recent European survey revealed that 80 percent of thoracic surgeons declared to follow the Enhanced Recovery After Surgery (ERAS) protocol, focussed on improving peri-operative lung cancer care,1...
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease
01 mai 2024 06h55 HE
|
Janssen Cilag International NV
Media contact:Sophie DaneauSdaneau@its.jnj.com+33 6 3178 8798Investor contact:Raychel Kruperinvestor-relations@its.jnj.com For European and UK medical and trade media only For immediate...
SWAV Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Shockwave Medical to Johnson & Johnson
10 avr. 2024 09h25 HE
|
Wohl & Fruchter LLP
We are investigating the fairness of the price of $335.00 per share in cash for which Shockwave Medical has agreed to be sold to Johnson & Johnson.
CURE Media Group and Oncology Nursing News Announces the 2024 Extraordinary Healer® Award Finalists
15 mars 2024 12h00 HE
|
CURE Media Group
CRANBURY, N.J., March 15, 2024 (GLOBE NEWSWIRE) -- CURE® Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to more than 1 million patients,...
PARP Inhibitor Market to Surpass USD 67.0 Billion by 2034, with 18.30% CAGR and Redefining Cancer Treatment Landscape - By PMI
27 févr. 2024 14h30 HE
|
PMI
Covina, Feb. 27, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the PARP Inhibitor Market size was valued at about USD 12.5 Billion in 2024 and expected to grow at CAGR of 18.30%...
Short Bowel Syndrome Market: “Improved Digestive Health with market Size & Share to Exceed USD 3060.8 Million by 2034, at CAGR of 13.70% – By PMI
15 févr. 2024 18h02 HE
|
PMI
Covina, Feb. 15, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Short Bowel Syndrome Market size was valued at about USD 850.5 Million in 2024 and expected to grow at CAGR of...
Biopharmaceutical and Biomedicine Market Size & Share to Exceed USD 1803.2 Billion by 2034, at CAGR of 12.20%. “Harnessing the Power of Genomics for Precision Medicine"– By PMI
12 févr. 2024 19h30 HE
|
PMI
Covina, Feb. 12, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Biopharmaceutical and Biomedicine Market size was valued at about USD 570.0 Billion in 2024 and expected to...
Light Therapy Market Size & Share to Exceed USD 1275.0 Million by 2034, at CAGR of 6.1%. "Radiant Revolution: Illuminating the Future of Light Therapy Markets" – PMI Leads the Way
01 févr. 2024 18h00 HE
|
PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Light Therapy Market size was valued at about USD 744.7 Million in 2024 and expected to grow at CAGR of 6.1% to...
AMAM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Ambrx Biopharma to Johnson & Johnson
08 janv. 2024 09h03 HE
|
Wohl & Fruchter LLP
We are investigating the fairness of the sale of Ambrx Biopharma to Johnson & Johnson.